Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide molecular signature study in eosinophilic COPD
NL-OMON59166Phase 4Recruiting
- Sponsor
- IDIBAPS
- Start
- Jun 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of budesonide in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by IDIBAPS. Primary endpoint: Molecular changes associated with ICS by eosinophil strata. Started Jun 2025; status: recruiting.
02
Drugs
budesonide
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON59166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59166.